Pharmacogenetics, race, and psychiatry: Prospects and challenges

Harvard Review of Psychiatry

Volumn 14, Issue 2, 2006, Pages 92-108

  Jones, David S ^a,b,c,e   Perlis, Roy H ^d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CAMBRIDGE HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NONE   (United States)

Author keywords

Ethnicity; Genetics; HapMap; History; Pharmacogenetics; Pharmacogenomics; Psychopharmacology; Race

Indexed keywords

ANTIDEPRESSANT AGENT; AZATHIOPRINE; CAPTOPRIL; CHOLINESTERASE; CLARITHROMYCIN; CLOZAPINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2D6; DEBRISOQUINE; DESIPRAMINE; DIAZEPAM; FLUOROURACIL; HALOPERIDOL; ISONIAZID; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; MORPHINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SPARTEINE; SUXAMETHONIUM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

AGE DISTRIBUTION; AGITATION; AGRANULOCYTOSIS; APNEA; AUTOIMMUNE DISEASE; BIPOLAR DISORDER; BLEEDING; BLOOD CLOTTING DISORDER; COMORBIDITY; COST BENEFIT ANALYSIS; DEPRESSION; DIET; DNA MICROARRAY; DNA POLYMORPHISM; DRUG ACETYLATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENVIRONMENTAL EXPOSURE; ENZYME INHIBITION; ETHNOLOGY; GENE EXPRESSION; GENE SEQUENCE; GENETIC DIFFERENCE; GENETIC RISK; GENETIC TRAIT; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEART ARRHYTHMIA; HEPATITIS; HUMAN; INSOMNIA; LOW DRUG DOSE; NEURITIS; NEUROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; POPULATION GENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; QUALITY ADJUSTED LIFE YEAR; RACE DIFFERENCE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TUBERCULOSIS; WEIGHT GAIN;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; POPULATION GROUPS; PSYCHOTROPIC DRUGS;

EID: 33645789567     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220600642895     Document Type: Review

References (157)

1. FDA approves testing of genes to personalize doses of drugs. Wall Street J 2005;12 Jan.
2. Kaplan A. Advances in pharmacogenomics reduce side effects and save lives. Psychiatr Times 2005;22(1):4-7.
3. Kahn J. How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics 2004;4:1-46.
4. Duster T. Medicine. Race and reification in science. Science 2005;307:1050-1.
5. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-73.
6. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-96.
7. Tate SK, Goldstein DB. Will tomorrow's medicines work for everyone? Nat Genet 2004;36(11 suppl):S34-42.
8. Melzer D, Raven A, Detmer DE, Ling T, Zimmern RL. My very own medicine: what I must know: information policy for pharmacogenetics. Cambridge: University of Cambridge, 2003. http://www.phgu.org.uk/about_phgu/pharmacogenetics.html
9. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002;11:2517-30.
10. Lin KM, Smith MW, Ortiz V. Culture and psychopharmacology. Psychiatr Clin North Am 2001;24:523-38.
11. Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. Yale J Biol Med 2002;75:221-31 [originally published 1902].
12. Bearn AG. Archibald Garrod and the individuality of man. New York: Oxford University Press, 1993.
13. Lindee MS. Moments of truth in genetic medicine. Baltimore: Johns Hopkins University Press, 2005.
14. Alving AS, Arnold J, Robinson DH, et al. Status of primaquine. JAMA 1952;149:1558-70.
15. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954;70:266-73.
16. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960;5197:485-91.
17. Dufour AP, Knight RA, Harris HW. Genetics of isoniazid metabolism in Caucasian, Negro, and Japanese populations. Science 1964;145:391.
18. Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 1977;22:251-8.
19. Lehmann H, Ryan E. The familial incidence of low pseudocholinesterase level. Lancet 1956;271:124.
20. Kalow W. Familial incidence of low pseudocholinesterase level. Lancet 1956;ii:576-7.
21. Kalow W, Gunn DR. The relation between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther 1957;120:203-14.
22. Kalow W, Gunn DR. Some statistical data on atypical cholinesterase of human serum. Ann Hum Genet 1959;23:239-50.
23. Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: Saunders, 1962.
24. Vogel F. Moderne Probleme der Humangenetik. Ergebnisse der inneren Medizin und Kinderheilkunde 1959;12:52-125.
25. Motulsky AG. Drug reactions, enzymes, and biochemical genetics. J Am Med Assoc 1957;165:835-7.
26. Axelrod J. An unexpected life in research. Annu Rev Pharmacol Toxicol 1988;28:1-23.
27. Conney AH. Induction of drug-metabolizing enzymes: a path to the discovery of multiple cytochromes P450. Annu Rev Pharmacol Toxicol 2003;43:1-30.
28. Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science 1968;161:72-3.
29. Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. Science 1968;159:1479-80.
30. Vesell ES. Intraspecies differences in frequency of genes directly affecting drug disposition: the individual factor in drug response. Pharmacol Rev 1978;30:555-63.
31. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
32. Alvan G, Bertilsson L, Dahl ML, Ingelman-Sundberg M, Sjoqvist F. Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. Drug Metab Dispos 2001;29(4 pt 2):580-5.
33. Kalow W. Pharmacogenetics: past and future. Life Sci 1990;47:1385-97.
34. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37.
35. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21.
36. Lin KM, Poland RE, Anderson D. Psychopharmacology, ethnicity, and culture. Transcultural Psychiatr Res 1995;32:3-40.
37. Kroemer HK, Eichelbauni M. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56:2285-98.
38. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
39. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
40. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.
41. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-6.
42. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8.
43. Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 2003;17:143-51.
44. Wang JH, Liu ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001;70:42-7.
45. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-71.
46. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-4.
47. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-9.
48. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000;20:105-7.
49. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-11.
50. Benedetti F, Serretti A, Colombo C, et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999;156:1450-2.
51. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001;58:539-44.
52. Rousseva A, Henry C, van den Bulke D, et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J 2003;3:101-4.
53. Serretti A, Artioli P, Zanardi R, et al. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl) 2004;174:504-11.
54. Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003;54:879-83.
55. Serretti A, Lorenzi C, Lilli R, Smeraldi E. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res 2000;34:89-98.
56. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998;8:259-68.
57. Masui T, Hashimoto R, Kusumi I, et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2006;9:83-88. Epub 2005 June 1.
58. Ebstein R, Horn-Saban S, Nemanov L, Shamir A, Belmaker RH, Agam G. Differential gene expression profiles due to lithium and bipolar disorder [Abstract]. Am J Med Genet 2000;96:482.
59. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002;63:942-7.
60. Lerer B. Understanding pharmacogenetics. Psychiatr Times 2003;20(5):37-9.
61. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000;355:1615-6.
62. Theisen FM, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005;15:285-9.
63. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359:2086-7.
64. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677-9.
65. Murphy GM, Jr., Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-5.
66. Murphy GM, Jr., Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-9.
67. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004;36:1319-25.
68. Shumyatsky GP, Malleret G, Shin RM, et al. Stathmin, a gene enriched in the amygdala, controls both learned and innate fear. Cell 2005;123:697-709.
69. Tomita T, Iwatsubo T. The inhibition of gamma-secretase as a therapeutic approach to Alzheimer's disease. Drug News Perspect 2004;17:321-5.
70. Espeseth AS, Xu M, Huang Q, et al. Compounds that bind APP and inhibit Aβ processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J Biol Chem 2005;280:17792-7.
71. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
72. Roses AD. Reducing pipeline attrition in clinical development via pharmacogenetics. Drug Discov Devel 2003(August):15.
73. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.
74. Saul S. FDA approves a heart drug for African-Americans. NY Times 2005;24 June.
75. Koppal T. Designing personalized medicines. Drug Discov Devel 2003(April):30-4.
76. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003;348:553-6.
77. Bovet P, Paccaud F. Race and responsiveness to drugs for heart failure. N Engl J Med 2001;345:766.
78. Noah L. Pharmacogenetics. N Engl J Med 2003;348:2041-3.
79. Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW. Difficulties in replication of results. Lancet 2000;356:1359-60.
80. Hirschhorn JN, Altshuler D. Once and again - issues surrounding replication in genetic association studies. J Clin Endocrinol Metab 2002;87:4438-41.
81. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 2005;437:1299-320.
82. Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004;129:36-40.
83. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004;305:217.
84. Zill P, Baghai TC, Zwanzger P, et al. SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 2004;9:1030-6.
85. Padrini R, Ferrari M. Pharmacogenetics. N Engl J Med 2003;348:2041-3.
86. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-50.
87. Richardson HL, Stier AR, Borsos-Nachtnebel E. Liver tumor inhibition and adrenal histologic responses in rats to which 3′-methyl-4- dimethylaminoazobenzene and 20-methylcholanthrene were simultaneously administered. Cancer Res 1952;12:356-61.
88. Conney AH, Burns JJ. Metabolic interactions among environmental chemicals and drugs. Science 1972;178:576-86.
89. Pantuck EJ, Hsiao KC, Conney AH, et al. Effect of charcoal-broiled beef on phenacetin metabolism in man. Science 1976;194:1055-7.
90. Pantuck EJ, Kuntzman R, Conney AH. Decreased concentration of phenacetin in plasma of cigarette smokers. Science 1972;175:1248-50.
91. Conney AH, Pantuck EJ, Hsiao KC, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1976;20:633-42.
92. Alvares AP, Pantuck EJ, Anderson KE, Kappas A, Conney AH. Regulation of drug metabolism in man by environmental factors. Drug Metab Rev 1979;9:185-205.
93. Derenne JL, Baldessarini RJ. Clozapine toxicity associated with smoking cessation: case report. Am J Ther 2005;12:469-71.
94. Alvares AP, Kappas A, Eiseman JL, et al. Intraindividual variation in drug disposition. Clin Pharmacol Ther 1979;26:407-19.
95. Breen R, Thornhill JT. Noncompliance with medication for psychiatric disorders. CNS Drugs 1998;9:457-71.
96. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153:993-1000.
97. Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry 2005;66:220-7.
98. Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956;124:484-5.
99. Kalow W. Race and therapeutic drug response. N Engl J Med 1989;320:588-90.
100. Wood AJ. Racial differences in the response to drugs - pointers to genetic differences. N Engl J Med 2001;344:1394-6.
101. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001;358:383-4.
102. Freedman ML, Reich D, Penney KL, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet 2004;36:388-93.
103. Gelernter J, Kranzler H, Cubells JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 1997;101:243-6.
104. Ruiz P, Varner RV, Small DR, Johnson BA. Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatr Q 1999;70:163-72.
105. Emsley RA, Roberts MC, Rataemane S, et al. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 2002;63:9-14.
106. Perlis RH, Sachs GS, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002;159:1155-9.
107. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215-9.
108. Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383-6.
109. Miskimen T, Marin H, Escobar J. Psychopharmacological research ethics: special issues affecting US ethnic minorities. Psychopharmacology (Berl) 2003;171:98-104.
110. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
111. Bonham VL, Warshauer-Baker E, Collins FS. Race and ethnicity in the genome era: the complexity of the constructs. Am Psychol 2005;60:9-15.
112. Jones DS. Rationalizing epidemics: meanings and uses of American Indian mortality since 1600. Cambridge: Harvard University Press, 2004.
113. Brandt AM. Racism and research: the case of the Tuskegee Syphilis Study. Hastings Cent Rep 1978;8(6):21-9.
114. Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000;61:344-8.
115. Reardon J. Race to the finish: Identity and governance in an age of genomics. Princeton, NJ: Princeton University Press, 2004.
116. Leroi AM. A family tree in every gene. NY Times 2005;14 March:A23.
117. Is race 'real'? [Social Science Research Council Web forum, 2005]. http://raceandgenomics.ssrc.org
118. Marks J. What it means to be 98% chimpanzee: apes, people, and their genes. Berkeley: University of California Press, 2002.
119. Tishkoff SA, Kidd KK. Implications of biogeography of human populations for 'race' and medicine. Nat Genet 2004;36(11 suppl):S21-7.
120. Jorde LB, Wooding SP. Genetic variation, classification and 'race.' Nat Genet 2004;36(11 suppl):S28-33.
121. Rosenberg NA, Pritchard JK, Weber JL, et al. Genetic structure of human populations. Science 2002;298:2381-5.
122. Mountain JL, Risch N. Assessing genetic contributions to phenotypic differences among 'racial' and 'ethnic' groups. Nat Genet 2004;36(11 suppl):S48-53.
123. Tang H, Quertermous T, Rodriguez B, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 2005;76:268-75.
124. Sinha M, Larkin EK, Elston RC, Redline S. Self-reported race and genetic admixture. N Engl J Med 2006;354:421-2.
125. The International HapMap Project. Nature 2003;426:789-96.
126. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006;38:68-74. Epub 2005 Nov 10.
127. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003;348:1170-5.
128. McLeod HL. Pharmacogenetics: more than skin deep. Nat Genet 2001;29:247-8.
129. McLeod HL. Race and responsiveness to drugs for heart failure. N Engl J Med 2001;345:766-7.
130. Phimister EG. Medicine and the racial divide. N Engl J Med 2003;348:1081-2.
131. Rotimi CN. Are medical and nonmedical uses of large-scale genomic markers conflating genetics and 'race'? Nat Genet 2004;36(11 suppl):S43-7.
132. Parra EJ, Kittles RA, Shriver MD. Implications of correlations between skin color and genetic ancestry for biomedical research. Nat Genet 2004;36(11 suppl):S54-60.
133. Keita SO, Kittles RA, Royal CD, et al. Conceptualizing human variation. Nat Genet 2004;36(11 suppl):S17-20.
134. Schwartz RS. Racial profiling in medical research. N Engl J Med 2001;344:1392-3.
135. Collins FS. What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era. Nat Genet 2004;36(11 suppl):S13-5.
136. Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med 2003;348:1166-70.
137. Jones DS. The persistence of American Indian health disparities. Am J Public Health 2006 (in press).
138. Royal CD, Dunston GM. Changing the paradigm from 'race' to human genome variation. Nat Genet 2004;36(11 suppl):S5-7.
139. The unexamined 'Caucasian.' Nat Genet 2004;36:541.
140. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989;320:565-70.
141. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-euzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
142. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65.
143. Wilson TW, Grim CE. Biohistory of slavery and blood pressure differences in blacks today. A hypothesis. Hypertension 1991;17(1 suppl):I122-8.
144. Curtin PD. The slavery hypothesis for hypertension among African Americans: the historical evidence. Am J Public Health 1992;82:1681-6.
145. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 2004;43:566-72.
146. Wilson JF, Weale ME, Smith AC, et al. Population genetic structure of variable drug response. Nat Genet 2001;29:265-9.
147. Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002;3:comment2007.1- 2007.12.
148. Risch N. Dissecting racial and ethnic differences. N Engl J Med 2006;354:408-11.
149. Genes, drugs and race. Nat Genet 2001;29:239-40.
150. Bloche MG. Race-based therapeutics. N Engl J Med 2004;351:2035-7.
151. Isaacs SL, Schroeder SA. Class - the ignored determinant of the nation's health. N Engl J Med 2004;351:1137-42.
152. Moyniham R. Report calls for better evaluation of pharmacogenetic tests. BMJ 2003;327:11.
153. Nierenberg AA, Feinstein AR. How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. JAMA 1988;259:1699-702.
154. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002;29:2507-12.
155. Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005;25:427-34.
156. Warner JH. The therapeutic perspective: medical practice, knowledge, and identity in America, 1820-1885. Cambridge: Harvard University Press, 1986.
157. Rosenberg C. The therapeutic revolution: medicine, meaning, and social change in nineteenth-century America. In: Explaining epidemics and other studies in the history of medicine. Cambridge: Cambridge University Press, 1992:9-31.